Five Years of Deferasirox Therapy for Cardiac Iron in β-Thalassemia Major

Hemoglobin

Volumn 39, Issue 5, 2015, Pages 299-304

  Vlachaki, Efthymia ^a   Agapidou, Alexandra ^a   Spanos, Georgios ^b   Klonizakis, Philippos ^a   Vetsiou, Evaggelia ^a   Mavroudi, Melahrini ^c   Boura, Panagiota ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Diagnostic Laboratory Tomografia   (Greece)

^c Aristotle University and Hippokration General Hospital   (Greece)

Author keywords

5 years; cardiac magnetic resonance imaging (MRI) T2 ; deferasirox (DFX); ferritin; left ventricular ejection fraction (LVEF); Thalassemia major ( TM)

Indexed keywords

CREATININE; DEFERASIROX; FERRITIN; LIVER ENZYME; BENZOIC ACID DERIVATIVE; IRON; IRON CHELATING AGENT; TRIAZOLE DERIVATIVE;

ADULT; CHELATION THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG ERUPTION; FEMALE; GASTROINTESTINAL SYMPTOM; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IRON CHELATION; IRON OVERLOAD; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; OUTCOME ASSESSMENT; POPULATION; PROSPECTIVE STUDY; REVIEW; THALASSEMIA MAJOR; TREATMENT DURATION; TREATMENT RESPONSE; BETA THALASSEMIA; BLOOD; CARDIOMYOPATHIES; COMPLICATION; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; BENZOATES; BETA-THALASSEMIA; CARDIOMYOPATHIES; FEMALE; FERRITINS; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; STROKE VOLUME; TREATMENT OUTCOME; TRIAZOLES; VENTRICULAR FUNCTION, LEFT; YOUNG ADULT;

EID: 84940740266     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630269.2015.1064003     Document Type: Review

References (34)

1. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187-1193.
2. Modell B, Khan M, Darlison M. Survival in β-thalassaemia major in the UK: Data from the UK Thalassaemia Register. Lancet. 2000;355(9220):2051-2052.
3. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95(1):26-36.
4. Brittenham GM, Weiss G, Brissot P, et al. Clinical consequences of new insights in the pathophysiology of disorders of iron and heme metabolism. Hematology Am Soc Hematol Educ Program. 2000:39-50.
5. Porter JB. Practical management of iron overload. Br J Haematol. 2001;115(2):239-252.
6. Kolnagou A, Economides C, Eracleous E, Kontoghiorghes GJ. Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2∗. Hemoglobin. 2006;30(2):219-227.
7. Glickstein H, El RB, Shvartsman M, Cabantchik ZI. Intracellular labile iron pools as direct targets of iron chelators: A fluorescence study of chelator action in living cells. Blood. 2005;106(9):3242-3250.
8. Glickstein H, El RB, Link G, et al. Action of chelators in iron-loaded cardiac cells: Accessibility to intracellular labile iron and functional consequences. Blood. 2006;108(9):3195-3203.
9. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2∗) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22(23):2171-2179.
10. Pennell DJ. T2∗ magnetic resonance and myocardial iron in thalassemia. Ann N Y Acad Sci. 2005;1054:373-378.
11. Modell B, Khan M, Darlison M, et al. Improved survival of thalassaemia major in the UK and relation to T2∗ cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;10:42. doi: 10.1186/1532-429X-10-42.
12. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331(9):567-573.
13. Fisher SA, Brunskill SJ, Doree C, et al. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. Cochrane Database Syst Rev. 2013;8:CD004450.
14. Fisher SA, Brunskill SJ, Doree C, et al. Oral deferiprone for iron chelation in people with thalassaemia. Cochrane Database Syst Rev. 2013;8:CD004839.
15. Tanner MA, Galanello R, Dessi C, et al. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson. 2008;10:12. doi: 10.1002/14651858.CD004839.pub3.
16. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115(14):1876-1884.
17. Cappellini MD, Bejaoui M, Agaoglu L, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with β-thalassemia. Clin Ther. 2007;29(5):909-917.
18. Cappellini MD, Taher MD. Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload. Expert Opin Pharmacother. 2008;9(13):2391-2402.
19. Haghpanah S, Zarei T, Zahedi Z, Karimi M. Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent β-thalassemia. Hematology. 2014;19(4):187-191.
20. Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006;91(7):873-880.
21. Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: A randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2003;361(9369):1597-1602.
22. Otto-Duessel M, Aguilar M, Nick H, et al. Comparison of twice-daily vs once-daily deferasirox dosing in a gerbil model of iron cardiomyopathy. Exp Hematol. 2007;35(7):1069-1073.
23. Wood JC, Kang BP, Thompson A, et al. The effect of deferasirox on cardiac iron in thalassemia major: Impact of total body iron stores. Blood. 2010;116(4):537-543.
24. Pennell DJ, Porter JB, Cappellini MD, et al. Deferasirox for up to 3 years leads to continued improvement of myocardial T2∗ in patients with β-thalassemia major. Haematologica. 2012;97(6):842-848.
25. Cassinerio E, Roghi A, Orofino N, et al. A 5-year follow-up in deferasirox treatment: Improvement of cardiac and hepatic iron overload and amelioration in cardiac function in thalassemia major patients. Ann Hematol. 2015;94(6):939-945.
26. Wood JC, Tyszka JM, Carson S, et al. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood. 2004;103(5):1934-1936.
27. Kirk P, Roughton M, Porter JB, et al. Cardiac T2∗ magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120(20):1961-1968.
28. Baksi AJ, Pennell DJ. Randomized controlled trials of iron chelators for the treatment of cardiac siderosis in thalassaemia major. Front Pharmacol. 2014;5:217. doi: 10.3389/fphar.2014.00217. eCollection 2014.
29. Pennell DJ, Porter JB, Piga A, et al. A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA). Blood. 2014;123(10):1447-1454.
30. Elalfy MS, Adly AM, Wali Y, et al. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron-overloaded young βthalassemia major patients. Eur J Haematol. 2015 Jan 20. doi: 10.1111/ejh.12507. [Epub ahead of print].
31. Pennell DJ, Porter JB, Piga A, et al. Sustained improvements in myocardial T2∗ over 2 years in severely iron-overloaded patients with β thalassemia major treated with deferasirox or deferoxamine. Am J Hematol. 2015;90(2):91-96.
32. Pathare A, Taher A, Daar S. Deferasirox (Exjade) significantly improves cardiac T2∗ in heavily iron-overloaded patients with β-thalassemia major. Ann Hematol. 2010;89(4):405-409.
33. Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia. Blood. 2010;115(12):2364-2371.
34. Taher A, Cappellini MD, Vichinsky E, et al. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol. 2009;147(5):752-759.